For more than a century, Hodgkin disease (HD) has served as a paradigm
for developing modern oncology concepts. Yet the success of using radiotherapy,
chemotherapy, or both for cure of a formerly lethal disease has not come without
a price.1-3 Even
though control of HD in early-stage and overall survival is approximately
90% at 10 years,4 survival is decreasing with
more years of observation, primarily due to a higher than expected number
of deaths from second malignancies. At 20 years after diagnosis, the cumulative
risk of developing second cancers is approximately 10%, exceeding the cumulative
risk of dying from the primary early-stage disease.4
Yahalom J. Breast Cancer After Hodgkin Disease: Hope for a Safer Cure. JAMA. 2003;290(4):529–531. doi:10.1001/jama.290.4.529
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: